SwedenSweden

Good safety profile

14.08.2008

BioInvent International AB (Lund) and ThromboGenics NV (Leuven, Belgium) will continue the development of their anti-angiogenic cancer antibody TB-403. After the antibody that targets placental growth factor (PIGF) showed good safety and pharmacokinetic properties in 16 healthy volunteers, the companies announced they will initiate a dose-escalation study in 30 patients with metastatic or unresectable solid tumours. The two firms are aiming to demonstrate that PIGF, in contrast to other anti-angiogenetic compounds, specifically targets neovascularisation in tumours.

SwedenSweden

14.04.2011

Stockholm – Swedish Orphan Biovitrum AB (SOBI) has reported weak results for 2010. The company’s net income declined by 7.7% to SEK1.9bn, with losses for the period totalling up to SEK104m. SOBI spokesmen said that several...

SwedenSweden

06.04.2011

Stockholm – Swedish Medivir AB has released good news on its lead compound TMC435. The protease inhibitor is intended for the therapy of treatment-naïve patients carrying the genotype-1 hepatitis C virus (HCV). In the PILLAR...

SwedenSweden

08.02.2011

Stockholm – At the end of last year, the first European patient was treated with Ruconest – a recombinant C1 esterase inhibitor for the treatment of hereditary acute angioedema attacks developed by the Dutch Pharming Group NV and...

SwedenSweden

10.12.2010

Lund/Jerusalem – Active Biotech’s oral small molecule immunomodulator laquinimod (ABR-215062) has reached the primary endpoint of statistically significant reduction in annualized relapse rate compared to placebo, according to...

SwedenSweden

04.11.2010

Stockholm – Swedish Orphan Biovitrum AB (Sobi) and Dutch partner Pharming Group NV received market authorisation for Ruconest (rhucin) at the end of October. Intended for use in acute attacks of Hereditary Angioedema (HAE), the...

SwedenSweden

25.10.2010

Stockholm - Swedish researchers have unravelled the three-dimensional structure of the egg receptor, paving the way for new treatments of infertility and novel contraceptives. The team headed by Luca Jovine at Karolinska...

SwedenSweden

16.09.2010

Uppsala – Orexo AB has announced a bold new strategy. The company listed on the Stockholm stock exchange intends to develop and commercialise its own products from now on rather than out-licensing them to international partners....

SwedenSweden

15.09.2010

Linköping – In the first clinical study of its kind, Swedish researchers have proven that biosynthetic corneas can offer a real alternative to rare human replacement corneas. In a process developed by Per Fagerholm and May...

Displaying results 21 to 30 out of 182

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/2/article/good-safety-profile.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.48 EUR3.77%
  • 4SC1.12 EUR2.75%
  • VITA 344.00 EUR2.04%

FLOP

  • ADDEX2.99 CHF-7.14%
  • BIOFRONTERA2.18 EUR-5.22%
  • SARTORIUS94.26 EUR-3.32%

TOP

  • SANTHERA92.00 CHF43.5%
  • CO.DON3.02 EUR26.9%
  • PAION2.98 EUR19.7%

FLOP

  • EVOTEC3.00 EUR-20.0%
  • ADDEX2.99 CHF-18.5%
  • 4SC1.12 EUR-15.8%

TOP

  • SANTHERA92.00 CHF2211.6%
  • CO.DON3.02 EUR247.1%
  • PAION2.98 EUR189.3%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.23 EUR-41.4%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 16.09.2014


Current issue

All issues

Product of the week

Products